GB:0RD1 Stock Latest News
Company AnnouncementsCamurus Sets Nomination Committee and Timetable for 2027 AGM1M ago
Company AnnouncementsCamurus’ Acromegaly Drug CAM2029 Resubmission Accepted by U.S. FDA3M ago
Company AnnouncementsCamurus AB Earnings Call Highlights Growth And Risks3M ago
Company AnnouncementsCamurus Delivers Record Product Sales and Strengthens Cash While Deepening Lilly Collaboration3M ago
Pre-EarningsCamurus AB (CAMRF) Q2 Earnings Cheat Sheet3M ago
Company AnnouncementsCamurus Boosts Share Count to Support Employee Incentive Plan4M ago
Company AnnouncementsCamurus Wins Lilly Option Exercise, Extending Long-Acting Cardiometabolic Drug Deal5M ago
Company AnnouncementsCamurus Repurchases Series C Shares to Fund Long-Term Incentive Plan5M ago
Company AnnouncementsCamurus AGM Backs Board, Withholds Dividend and Approves New Performance Share Plan5M ago
Company AnnouncementsCamurus Holds Course on 2026 Outlook Despite Softer Q1 Sales5M ago
Company AnnouncementsCamurus Targets Severe Diseases With Long-Acting Drug Innovations6M agoCompany AnnouncementsCamurus calls 2026 AGM with capital measures and new incentive plan on agenda6M ago
- Company AnnouncementsCamurus Expands Share Capital After Employee Stock Option Exercises8M ago
- Company AnnouncementsCamurus Strengthens Executive Team With New Corporate Development Chief8M ago
Company AnnouncementsCamurus AB Earnings Call: Growth, FX and U.S. Push8M ago
Company AnnouncementsCamurus Posts Strong 2025 Earnings, Expands Long-Acting Endocrine Portfolio8M ago
Pre-EarningsCAMRF Upcoming Earnings Report: What to Expect?8M ago
Company AnnouncementsCamurus’ acromegaly drug Oclaiz gains FDA review date after resubmitted US filing9M ago